Most Read Articles
6 days ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course

Coping intervention ineffective for reducing anxiety in siblings of children with cancer

09 Apr 2018

The Siblings Coping Together (SibCT) group intervention method does not appear to have significant positive effects on anxiety symptoms of siblings of children with cancer, a recent study has shown.

The researchers randomized 75 healthy siblings (aged 7–16 years; 41 males) of paediatric cancer patients to either the SibCT treatment (n=41) or to attention control (n=34). Study outcome was anxiety symptoms, measured using the Multidimensional Anxiety Scale for Children (MASC).

SibCT had no significant effect on the total MASC score or on the scores in the individual subsets. Scores were unaffected when analysed according to participant group or across time. At baseline, 28 percent of males and 17 percent of females had elevated MASC scores, though the difference did not reach statistical significance.

Multivariable analysis showed that there was a significant gender influence, such that MASC scores were significantly higher in the male vs female siblings across both groups and all assessment times (p<0.05).

Researchers also assessed the effect of SibCT on caregiver anxiety and found that there was a significant medium-sized reduction in anxiety symptoms over time, according to the total Multidimensional Anxiety Questionnaire (MAQ) scores (p<0.02). However, no significant group-by-time effect was observed.

Additionally, caregiver scores in the physiological/panic subscale of the MAQ were significantly higher when the child with cancer was actively receiving treatment than when off treatment (p<0.04). Analysis by treatment group showed that, when the ill child is on active treatment, caregivers of siblings receiving SibCT had significantly fewer panic reactions than their counterparts in the control group (p<0.03).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
In advanced-stage, newly diagnosed classical, CD30-positive Hodgkin lymphoma (HL), front-line therapy has resulted in durable remission rates in up to 70–90% of patients, although approximately 25–30% of advanced stage HL patients are refractory or relapse following first-line treatment with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) chemotherapy.1–3 The standard of care for patients with relapsed or refractory (r/r) classical HL is salvage therapy using second-line high-dose chemotherapy (HDCT), followed by autologous haematopoietic stem cell transplant (ASCT) in eligible patients, which can induce a complete remission (CR) in about 50% of patients.4 Nevertheless, the prognosis of patients who relapse after the salvage HDCT/ASCT is exceedingly poor, with a median survival duration of approximately 1.2 years.5
29 Nov 2017
Rapid onset opioids may allow for more effective treatment of breakthrough cancer pain as their pharmacokinetic profile closely mimics the pain’s time course